Experience

Cidara Therapeutics Announces Concurrent Reacquisition of IP Rights to CD388, $240 Million PIPE Financing

May 1, 2024

Cooley advised Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, on its concurrent $240 million private placement financing and definitive agreement with Janssen Pharmaceuticals, a Johnson & Johnson Company, to reacquire the exclusive global development and commercial rights to CD388.

Read more

Related contacts

Charles Bair
Partner, San Diego
Jane Adams
Partner, San Diego
Barbara Borden
Senior Counsel, San Diego
Megan Browdie
Partner, Washington, DC
Daniel I. Goldberg
Partner, New York
Aaron Pomeroy
Partner, Colorado
Richard Segal
Partner, New York
Francis Wheeler
Senior Counsel, Colorado
Sharon Connaughton
Special Counsel, Washington, DC
Asa Henin
Partner, San Diego
Gaël Y. Hagan
Special Counsel , Colorado
Michelle Hunt
Associate
Edmond Lay
Partner, San Diego
Kyrsten Lundh
Associate, San Diego
Amanda Pacheco
Associate, Palo Alto
Valerie Sapozhnikova
Associate, Los Angeles
Kelly Nelle
Paralegal Specialist, San Diego

Related Practices & Industries

RayzeBio Announces Upsized $357.6 Million IPO

September 19, 2023

Cooley advised RayzeBio, a targeted radiopharmaceutical company developing an innovative pipeline against solid tumor targets, on its upsized $357.6 million initial public offering.

Read more

Related contacts

Carlos Ramirez
Partner, San Diego
Charlie Kim
Partner, San Diego
Marya Postner
Partner, Palo Alto
Valerie Sapozhnikova
Associate, Los Angeles
Michelle Hunt
Associate
Todd Gluth
Partner, San Diego
Tony P. Guan
Associate, Santa Monica
Nathaniel Hearn Jr.
Associate, Chicago
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York
Alessandra Murata
Partner, Palo Alto
Kelly Nelle
Paralegal Specialist, San Diego
Rebecca Ross
Special Counsel, Washington, DC
Jeffrey J. Tolin
Partner, New York
Francis Wheeler
Senior Counsel, Colorado

Related Practices & Industries

Poseida Therapeutics – $80.5 Million Follow-on Offering

September 7, 2022

Cooley advised the issuer for Poseida Therapeutics’ $80.5 million follow-on offering of 23,000,000 shares of common stock at a public offering price of $3.50 per share. Poseida is a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary genetic engineering platform technologies to create next-generation cell and gene therapeutics. Partners Tom Coll and Charlie Kim led the Cooley team.

Related contacts

Tom Coll
Partner, San Diego
Charlie Kim
Partner, San Diego
Asa Henin
Partner, San Diego
Edmond Lay
Partner, San Diego
Heidi E. Wang
Associate, San Diego
Stephanie Leigh
Paralegal Specialist, San Diego
Kelly Nelle
Paralegal Specialist, San Diego

Related Practices & Industries

The Underwriters On Guardant Health's $1.1 Billion Follow-On Offering

June 8, 2020

Advised underwriters on Guardant Health's $1.1 billion follow-on offering. Guardant Health, whose securities trade on the Nasdaq Global Select Market under the symbol “GH”, is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics

Related contacts

David Peinsipp
Partner, San Francisco
Charlie Kim
Partner, San Diego
Kristin VanderPas
Partner, San Francisco
Denny Won
Partner, San Francisco
Kelly Nelle
Paralegal Specialist, San Diego

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.